Jazz Pharmaceuticals Announces Second Quarter 2017 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
Jazz Pharmaceuticals (JAZZ) Misses Q2 EPS by 19c
August 8, 2017 4:16 PM EDTJazz Pharmaceuticals (NASDAQ: JAZZ) reported Q2 EPS of $2.56, $0.19 worse than the analyst estimate of $2.75. Revenue for the quarter came in at $394.4 million versus the consensus estimate of $410.82 million.
"Thus far, 2017 has been a highly productive year. We have executed on and delivered results of key... More
